- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
LeonaBio Inc (LONA)
LeonaBio Inc stock price live, this page displays NASDAQ LONA stock exchange data. View the LONA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the LeonaBio Inc real time stock price chart below.
What Is the LeonaBio Inc Stock Price Today?
The LeonaBio Inc stock price today is 7.570.
What Is the Stock Symbol for LeonaBio Inc?
The stock symbol for LeonaBio Inc is "LONA."
What Stock Exchange Does LeonaBio Inc Trade On?
LeonaBio Inc is listed and trades on the NASDAQ stock exchange.
Is LeonaBio Inc a Good Stock to Buy?
Determining whether LeonaBio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LONA quote. (ISIN: US04746L2034)
What Is the LeonaBio Inc Stock Price Today?
The LeonaBio Inc stock price today is 7.570.
What Is the Stock Symbol for LeonaBio Inc?
The stock symbol for LeonaBio Inc is "LONA."
What Stock Exchange Does LeonaBio Inc Trade On?
LeonaBio Inc is listed and trades on the NASDAQ stock exchange.
Is LeonaBio Inc a Good Stock to Buy?
Determining whether LeonaBio Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LONA quote. (ISIN: US04746L2034)
NASDAQ
Currency in USD
7.570
-0.260(-3.32%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.570
8.110
52 wk Range
3.525
14.210
LONA is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.5708.110
52 wk Range
3.52514.210
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LONA Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Strong Buy
Price Target
17.333
Upside
+128.97%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
LeonaBio beats second quarter loss estimates- Investing.com
- LeonaBio beats second quarter loss estimates
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 17.333
(+128.97% Upside)
LeonaBio Inc SWOT Analysis
ALS Drug Promise | Athira Pharma's ATH-1105 shows potential in ALS treatment, with positive preclinical data and Phase 1 results driving future clinical plans |
Financial Crossroads | Despite $37M cash reserves, Athira faces financial challenges. Market cap decline to $9.8M reflects investor caution amid strategic shifts |
Strategic Pivot | Explore Athira's strategic review process and pursuit of partnerships to accelerate ATH-1105 development and enhance shareholder value |
Market Sentiment | Analyst ratings hold at "Market Perform" without price targets, reflecting cautious optimism as Athira advances its focused ALS program |
Earnings
Latest Release
Aug 17, 2026
EPS / Forecast
-0.80 / -1.12
Revenue / Forecast
-- / --
Compare LONA to Peers and Sector
Metrics to compare | LONA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLONAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.5x | 6.0x | −0.3x | |
PEG Ratio | −0.02 | −0.18 | 0.00 | |
Price/Book | 2.2x | −7.8x | 2.6x | |
Price / LTM Sales | - | 2.3x | 3.1x | |
Upside (Analyst Target) | 117.1% | 49.8% | 48.5% | |
Fair Value Upside | Unlock | 5.8% | 6.3% | Unlock |
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company’s lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of diabetic neuropathy, which is in phase 1 clinical trial; and ATH-1017 for the treatment of Alzheimer’s disease and Parkinson’s disease, which is in phase 2 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the LeonaBio (LONA) Stock Price Today?
The LeonaBio stock price today is 7.570 USD.
What Stock Exchange Does LeonaBio Trade On?
LeonaBio is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for LeonaBio?
The stock symbol for LeonaBio is "LONA."
What Is the LeonaBio Market Cap?
As of today, LeonaBio market cap is 72.520M USD.
What Is LeonaBio's Earnings Per Share (TTM)?
The LeonaBio EPS (TTM) is -10.877.
When Is the Next LeonaBio Earnings Date?
LeonaBio will release its next earnings report on Nov 05, 2026.
From a Technical Analysis Perspective, Is LONA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has LeonaBio Stock Split?
LeonaBio has split 1 times.
How Many Employees Does LeonaBio Have?
LeonaBio has 19 employees.
What is the current trading status of LeonaBio (LONA)?
As of Aug 20, 2026, LeonaBio (LONA) is trading at a price of 7.570 USD, with a previous close of 7.830 USD. The stock has fluctuated within a day range of 7.570 USD to 8.110 USD, while its 52-week range spans from 3.525 USD to 14.210 USD.
What Is LeonaBio (LONA) Price Target According to Analysts?
The average 12-month price target for LeonaBio is 17.333 USD, with a high estimate of 20 USD and a low estimate of 15 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +128.97% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.